In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y
Annals of Internal Medicine（2022）
摘要
Kim BK, Hong SJ, Lee YJ, et al. Lancet. 202;400:380-90. 35863366.
更多查看译文
关键词
ezetimibe,moderate-intensity,high-intensity
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要